Zenas BioPharmaの空売り状況は、投資家がZenas BioPharmaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Zenas BioPharma (NASDAQ:ZBIO) 株価情報, 空売り情報

Zenas BioPharma

ProShares UltraPro Short NASDAQ Biotechnology

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Zenas BioPharma Inc

Earnings

Earnings Beats

News

NBBK

NB Bancorp Q4 2024 EPS $0.34 Beats $0.32 Estimate

<p><strong>QCR Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCRH#NASDAQ">QCRH</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:05 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>QCR Hldgs beat estimated earnings by 10.0%, reporting an EPS of $1.93 versus an estimate of $1.76.</p>
<p>Revenue was up $5.47 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.26 which was followed by a 0.0% increase in the share price the next day.</p>
<p>Here's a look at QCR Hldgs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.52</td>
<td>1.40</td>
<td>1.30</td>
<td>1.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.78</td>
<td>1.73</td>
<td>1.59</td>
<td>1.97</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>61.47M</td>
<td>65.25M</td>
<td>63.77M</td>
<td>58.53M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>59.72M</td>
<td>56.16M</td>
<td>54.70M</td>
<td>55.74M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for QCR Hldgs <a href="https://www.benzinga.com/quote/QCRH/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


QCRH

QCR Hldgs Earnings Analysis: Q4 Recap

<p><strong>Triumph Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:07 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Triumph Financial missed estimated earnings by -48.0%, reporting an EPS of $0.13 versus an estimate of $0.25.</p>
<p>Revenue was down $2.59 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.01 which was followed by a 5.0% increase in the share price the next day.</p>
<p>Here's a look at Triumph Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.18</td>
<td>0.22</td>
<td>0.34</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.19</td>
<td>0.08</td>
<td>0.14</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>107.30M</td>
<td>104.08M</td>
<td>106.01M</td>
<td>106.85M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>106.20M</td>
<td>105.08M</td>
<td>101.03M</td>
<td>106.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Triumph Financial <a href="https://www.benzinga.com/quote/TFIN/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TFIN

Triumph Financial Earnings Analysis: Q4 Recap

<p>Towne Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOWN#NASDAQ">TOWN</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.48 by 14.58 percent. This is a 30.95 percent increase over earnings of $0.42 per share from the same period last year.  The company reported quarterly sales of $177.16 million which beat the analyst consensus estimate of $170.78 million by 3.74 percent.  This is a 13.90 percent increase over sales of $155.55 million the same period last year.</p>


TOWN

Towne Bank Q4 Adj $0.55 Beats $0.48 Estimate, Sales $177.16M Beat $170.78M Estimate

<p>The earnings results for <strong>SL Green Realty</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) for Q4 were made public on Wednesday, January 22, 2025 at 04:10 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>SL Green Realty beat estimated earnings by 18.0%, reporting an EPS of $1.81 versus an estimate of $1.53.</p>
<p>Revenue was up $7.69 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company missed on EPS by $0.07, resulting in a 3.0% increase change in the share price the following day.</p>
<p>Here's a look at SL Green Realty's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.20</td>
<td>1.60</td>
<td>2.16</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.13</td>
<td>2.05</td>
<td>3.07</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>136.66M</td>
<td>149.28M</td>
<td>152.67M</td>
<td>161.36M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>139.62M</td>
<td>135.56M</td>
<td>128.20M</td>
<td>131.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for SL Green Realty <a href="https://www.benzinga.com/quote/SLG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SL Green Realty Q4 Earnings Assessment

<p>The Q4 earnings report for <strong>Hexcel</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) was released on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hexcel missed estimated earnings by 0.0%, reporting an EPS of $0.52 versus an estimate of $0.52.</p>
<p>Revenue was up $16.30 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Hexcel's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.46</td>
<td>0.56</td>
<td>0.41</td>
<td>0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.47</td>
<td>0.60</td>
<td>0.44</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>456.90M</td>
<td>483.36M</td>
<td>473.78M</td>
<td>471.69M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>456.50M</td>
<td>500.40M</td>
<td>472.30M</td>
<td>457.50M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Hexcel <a href="https://www.benzinga.com/quote/HXL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Hexcel Q4 Earnings

<p>The earnings results for <strong>Plexus</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) for Q1 were made public on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Plexus beat estimated earnings by 9.0%, reporting an EPS of $1.73 versus an estimate of $1.59.</p>
<p>Revenue was down $6.88 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.3 in the last quarter, resulting in a 7.000000000000001% increase share price change the following day.</p>
<p>Here's a look at Plexus's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.55</td>
<td>1.30</td>
<td>0.87</td>
<td>1.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.85</td>
<td>1.45</td>
<td>0.94</td>
<td>1.04</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.01B</td>
<td>981.25M</td>
<td>950.83M</td>
<td>987.63M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.05B</td>
<td>961.00M</td>
<td>967.00M</td>
<td>983.00M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Plexus management provided guidance for Q2 2025, expecting earnings between $1.46 and $1.61 per share.</p>
<p>To track all earnings releases for Plexus <a href="https://www.benzinga.com/quote/PLXS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PLXS

Plexus: Q1 Earnings Insights

<p><strong>National Bank Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) released its Q4 earnings on Wednesday, January 22, 2025 at 04:10 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>National Bank Holdings beat estimated earnings by 12.0%, reporting an EPS of $0.86 versus an estimate of $0.77.</p>
<p>Revenue was up $600 thousand from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 8.0% increase share price change the next day.</p>
<p>Here's a look at National Bank Holdings's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.75</td>
<td>0.74</td>
<td>0.76</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.86</td>
<td>0.68</td>
<td>0.82</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>104.59M</td>
<td>102.96M</td>
<td>103.68M</td>
<td>103.96M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>106.04M</td>
<td>97.60M</td>
<td>101.72M</td>
<td>107.23M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for National Bank Holdings <a href="https://www.benzinga.com/quote/NBHC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NBHC

Earnings Breakdown: National Bank Holdings Q4

<p><strong>CACI International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) reported its Q2 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>CACI International beat estimated earnings by 13.0%, reporting an EPS of $5.95 versus an estimate of $5.25.</p>
<p>Revenue was up $266.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.86 in the last quarter, resulting in a 5.0% increase share price change the following day.</p>
<p>Here's a look at CACI International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>5.07</td>
<td>5.93</td>
<td>5.63</td>
<td>4.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>5.93</td>
<td>6.61</td>
<td>5.74</td>
<td>4.36</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.92B</td>
<td>1.93B</td>
<td>1.86B</td>
<td>1.84B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.06B</td>
<td>2.04B</td>
<td>1.94B</td>
<td>1.83B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>CACI International management provided guidance for FY 2025, expecting earnings between $23.87 and $24.76 per share.</p>
<p>To track all earnings releases for CACI International <a href="https://www.benzinga.com/quote/CACI/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CACI

CACI International Earnings Review: Q2 Summary

<p><strong>Third Coast Bancshares</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBX#NASDAQ">TCBX</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Third Coast Bancshares beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.79 versus an estimate of $0.69.</p>
<p>Revenue was up $6.82 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat on EPS by $0.2 which was followed by a 6.0% increase in the share price the next day.</p>
<p>Here's a look at Third Coast Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.57</td>
<td>0.49</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.74</td>
<td>0.63</td>
<td>0.61</td>
<td>0.57</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>41.67M</td>
<td>41.13M</td>
<td>39.30M</td>
<td>38.13M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>42.90M</td>
<td>41.75M</td>
<td>40.42M</td>
<td>39.49M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Third Coast Bancshares <a href="https://www.benzinga.com/quote/TCBX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TCBX

Third Coast Bancshares Q4 Earnings Assessment

<p>The earnings results for <strong>Wesbanco</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>) for Q4 were made public on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Wesbanco beat estimated earnings by 28.999999999999996%, reporting an EPS of $0.71 versus an estimate of $0.55.</p>
<p>Revenue was up $8.75 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company beat on EPS by $0.05, resulting in a 1.0% drop change in the share price the following day.</p>
<p>Here's a look at Wesbanco's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.53</td>
<td>0.55</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.56</td>
<td>0.49</td>
<td>0.56</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>120.74M</td>
<td>126.11M</td>
<td>116.83M</td>
<td>116.77M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>121.14M</td>
<td>116.59M</td>
<td>113.97M</td>
<td>117.76M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Wesbanco <a href="https://www.benzinga.com/quote/WSBC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WSBC

Wesbanco Earnings Analysis: Q4 Recap

<p><strong>Univest Financial</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UVSP#NASDAQ">UVSP</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Univest Financial beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.65 versus an estimate of $0.57.</p>
<p>Revenue was up $5.42 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>Last quarter the company beat on EPS by $0.09 which was followed by a 4.0% increase in the share price the next day.</p>
<p>Here's a look at Univest Financial's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.54</td>
<td>0.51</td>
<td>0.51</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.63</td>
<td>0.61</td>
<td>0.60</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>73.20M</td>
<td>72.30M</td>
<td>72.20M</td>
<td>71.25M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>73.35M</td>
<td>72.01M</td>
<td>77.06M</td>
<td>71.38M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Univest Financial <a href="https://www.benzinga.com/quote/UVSP/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


UVSP

Univest Financial Earnings Review: Q4 Summary

<p><strong>Equity Bancshares</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) just disclosed its Q4 earnings on Wednesday, January 22, 2025 at 04:45 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Equity Bancshares beat estimated earnings by 13.0%, reporting an EPS of $1.04 versus an estimate of $0.92.</p>
<p>Revenue was up $62.24 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.32, resulting in a 2.0% increase change in the share price the following day.</p>
<p>Here's a look at Equity Bancshares's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.99</td>
<td>0.92</td>
<td>0.85</td>
<td>-1.88</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.31</td>
<td>0.99</td>
<td>0.90</td>
<td>-1.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>56.09M</td>
<td>55.15M</td>
<td>52.81M</td>
<td>29.49M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>55.35M</td>
<td>55.43M</td>
<td>55.91M</td>
<td>-3M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Equity Bancshares <a href="https://www.benzinga.com/quote/EQBK/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EQBK

Earnings Breakdown: Equity Bancshares Q4

<p>Shares of solar stocks, including <strong>First Solar Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) and <strong>SolarEdge Technologies, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) were volatile Wednesday as investors reacted to President Donald Trump&#8217;s newly signed <a href="https://www.benzinga.com/25/01/43109461/gold-miners-defense-stocks-shine-while-solar-tanks-following-trumps-day-1-actions">executive orders promoting </a>fossil fuels and reversing climate-focused policies.</p>
<p><strong>What To Know: </strong> The sell-off followed Trump's inauguration and his immediate signature on executive orders prioritizing oil and gas development over renewable energy initiatives.</p>
<p>According to<a href="https://www.nytimes.com/2025/01/20/climate/trump-emergency-oil-gas.html"> the New York Times</a>, his administration announced plans to withdraw from the Paris Agreement, expand fossil fuel drilling on public lands and waters, and eliminate regulatory support for electric vehicles and renewable energy projects. Trump also declared a national energy emergency aimed at accelerating fossil fuel production, further unsettling renewable energy investors.</p>
<p>The market&#8217;s response may reflect concerns over the new administration's shift in energy policy, which contrasts sharply with the pro-renewable initiatives under the previous Biden administration. Analysts believe this pivot could slow the growth of the renewable energy sector and significantly impact solar companies, contributing to the downward pressure on their stock prices.</p>
<p><strong>Price Action: </strong>First Solar&#8217;s stock closed Wednesday at $171.90, down 6.33%, and SolarEdge Technologies closed at $13.05, down 4.74%, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/43144023/riot-stock-poised-break-out-consolidation-cycle">Options Corner: Riot Platforms Could Be Itching To Charge Higher</a></strong></li>
</ul>
<p><em>Photo: solarseven on Shutterstock</em>.</p>


Government

Movers

FSLR

SEDG

Solar Shares Are Volatile Today: What's Going On?

<p>CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.88 percent. This is a 7.69 percent decrease over earnings of $0.39 per share from the same period last year.</p>


CVBF

CVB Financial Q4 EPS $0.36 Beats $0.34 Estimate

WIIM

BETR

Better Home & Finance shares are trading higher after the company announced a $25 million share repurchase program.

<p>Jean Madar, Chairman &amp; Chief Executive Officer of Interparfums, stated, "Our net sales in the final quarter of 2024 marked our best-ever fourth quarter performance, with quarterly sales growth of 10%, enabling us to achieve our 2024 sales goal of $1.45 billion."</p>
<p>Achieving the sales goal of $1.45 billion positions the Company to meet its full year 2024 earnings per diluted share target of $5.15, excluding a supplemental non-recurring, non-cash impairment charge of approximately $0.07 per diluted share, associated with trademarks.</p>


Guidance

IPAR

Interparfums Q4 Net Sales Up 10% To $362M, Est $361.807M

Macro Economic Events

Econ #s

Economics

API Weekly Crude Stock: 1M Barrel Build

<p><strong>Knight-Swift</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) reported its Q4 earnings results on Wednesday, January 22, 2025 at 04:02 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Knight-Swift beat estimated earnings by 9.0%, reporting an EPS of $0.36 versus an estimate of $0.33.</p>
<p>Revenue was down $67.72 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company beat on EPS by $0.02 in the previous quarter, leading to a 2.0% drop share price change the next day.</p>
<p>Here's a look at Knight-Swift's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.28</td>
<td>0.20</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>0.24</td>
<td>0.12</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.91B</td>
<td>1.83B</td>
<td>1.82B</td>
<td>1.97B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.88B</td>
<td>1.85B</td>
<td>1.82B</td>
<td>1.93B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Knight-Swift management provided guidance for Q2 2025, expecting earnings between $0.46 and $0.5 per share.</p>
<p>To track all earnings releases for Knight-Swift <a href="https://www.benzinga.com/quote/KNX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Knight-Swift: Q4 Earnings Insights

<p><strong>Fourth Quarter and Full Year 2024 Preliminary Results</strong></p>
<p>For the fourth quarter 2024, Concentra expects to report:</p>
<ul>
<li>Revenue of $465.0 million, an increase of 5.5% over Q4 2023</li>
<li>Net income in the range of $20.6 million to $22.6 million, compared to $28.9 million in Q4 2023</li>
<li>Adjusted EBITDA of $77.5 million, an increase of 13.6% over Q4 2023</li>
<li>Patient Visits of 2,994,988, or 46,797 Visits per Day, a decrease in Visits per Day of 2.1% from Q4 2023</li>
<li>Revenue per Visit of $145.08, an increase of 5.8% over Q4 2023</li>
<li>Capital Expenditures of $18.1 million, compared to $23.6 million in Q4 2023</li>
<li>Total occupational health centers of 552, compared to 544 at end of Q4 2023</li>
<li>Total onsite health clinics of 157, compared to 150 at end of Q4 2023</li>
</ul>
<p>For full year 2024, Concentra expects to report:</p>
<ul>
<li>Revenue of $1,900.2 million, an increase of 3.4% over FY 2023</li>
<li>Net income in the range of $169.7 million to $171.7 million, compared to $184.7 million in FY 2023</li>
<li>Adjusted EBITDA of $376.9 million, an increase of 4.3% over FY 2023</li>
<li>Cash balance of $183.3 million and net leverage ratio of approximately 3.5x</li>
<li>Patient Visits of 12,623,503, or 49,311 Visits per Day in the quarter, a decrease in Visits per Day of 2.0% from FY 2023</li>
<li>Revenue per Visit of $141.30, an increase of 4.5% over FY 2023</li>
<li>Capital Expenditures of $65.7 million, compared to $65.0 million in FY 2023</li>
</ul>


Concentra Announces Preliminary Q4 2024 Revenue Of $465M, Up 5.5%, Net Income $20.6M-$22.6M; FY24 Revenue $1.9B, Up 3.4%, Net Income $169.7M-$171.7M; Q4 Adjusted EBITDA Up 13.6% To $77.5M; FY Adjusted EBITDA Up 4.3% To $376.9M; Patient Visits Down 2.1%; CapEx $18.1M In Q4

Zenas BioPharma, Inc. (ZBIO) has received a new Buy rating, initiated by Morgan Stanley analyst, Vikram Purohit. Vikram Purohit has given his Buy r...

Buy Rating on Zenas BioPharma: Promising Obexelimab Trials Signal Market Potential and Stock Appreciation

Zenas BioPharma, Inc. (ZBIO) has received a new Buy rating, initiated by Guggenheim analyst, Yatin Suneja. Yatin Suneja's rating is based on a comp...

Buy Rating Justified for Zenas BioPharma on Strong Potential of Lead Asset Obexelimab

Zenas started at buy by four banks on lead drug potential

Zenas Bio: Recent IPO With Late-Stage Candidate

"In the third quarter, we successfully completed our initial public offering, providing capital to fund our growth strategy for the Company and exp...

Zenas BioPharma reports Q3 EPS ($5.02), consensus ($9.33)

Zenas BioPharma, Inc. GAAP EPS of -$5.02

Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Pur...

Zenas BioPharma's Promising Pipeline and Strategic Moves Earn Buy Rating

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Zenas BioPharma, Inc. (ZBIO – Research Report), with a pr...

Strategic Shift and Positive Outlook Justify Buy Rating for Zenas BioPharma, Inc.

H.C. Wainwright initiated coverage of Zenas BioPharma (ZBIO) with a Buy rating and $30 price target The company's lead autoimmune therapy, obexelim...

Zenas BioPharma initiated with a Buy at H.C. Wainwright

Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Roger Song...

Comments

Zenas BioPharma

空売り

Zenas BioPharma (NASDAQ:ZBIO) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル